Impact of risk minimisation measures on the use of strontium ranelate: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance
Autors principals: | Berencsi, K, Ali, M, Marinier, K, Deltour, N, Hawley, S, Pedersen, L, Rijnbeek, P, Duijnhoven, R, Van Der Lei, J, Lapi, F, Simonetti, M, Reyes-Reyes, C, Sturkenboom, M, Prieto-Alhambra, D |
---|---|
Format: | Conference item |
Publicat: |
Wiley
2017
|
Ítems similars
-
Impact of risk minimisation measures on the use of strontium ranelate: A multinational cohort study in 5 EU countries by the EU‐ADR Alliance
per: Berencsi, K, et al.
Publicat: (2018) -
Comparative cardiovascular safety of strontium ranelate and bisphosphonates amongst patients with no contraindications: a multi-database study in our European countries by the EU-ADR Alliance
per: Ali, M, et al.
Publicat: (2017) -
Comparative cardiovascular safety of strontium ranelate and bisphosphonates amongst patients with no contraindications: A multi‐database study in 5 EU countries by the EU‐ADR Alliance
per: Ali, M, et al.
Publicat: (2018) -
A multi-database, multinational validation study of cardiovascular death, venous thromboembolic events and gastrointestinal diseases in the EU-ADR Alliance
per: Ying, H, et al.
Publicat: (2018) -
The impact of risk minimisation measures on the incidence and prevalence of use of strontium ranelate at the population level: preliminary results of a multi-national cohort study including 5 European countries
per: Berencsi, K, et al.
Publicat: (2016)